David Gerber, MD
Dr. Gerber is a medical oncologist specializing in treating patients with lung cancer at UT Southwestern Medical Center and the Harold C. Simmons Comprehensive Cancer Center. Dr. Gerber is actively involved in researching the use of targeted therapies to treat this difficult disease, and believes that his role as a physician for patients with cancer extends beyond administering chemotherapy: he says that it also includes providing psychosocial support. “Providing support throughout the process is a role that I cherish.”[1]
Education and Career
Dr. Gerber attended Yale University in New Haven, Connecticut as an undergraduate. He graduated cum laude with a bachelor’s degree in History, then went on to earn his medical degree at Cornell University Medical College in New York. He completed an internship and residency in Internal Medicine at UT Southwestern, where he served as chief resident, then completed advanced training in the form of a fellowship in Medical Oncology at Johns Hopkins University School of Medicine in Baltimore, Maryland.[1]
Dr. Gerber is board-certified in Internal Medicine and Medical Oncology. He is the David Bruton Jr., Professor in Clinical Cancer Research, is a member of the Division of Hematology/Oncology, is a Co-Director of the Experimental Therapeutics Program, and serves on several committees at UT Southwestern.
Professional Memberships
- American Society of Clinical Oncology’s Lung Cancer Education Committee
- International Association for the Study of Lung Cancer’s Career Development Committee
- Editorial board of the Journal of Clinical Oncology
Research
Dr. Gerber is an active researcher of oncology outcomes with a special interest in lung cancer. He is the Co-Director of UT Southwestern’s Experimental Therapeutics Program, which aims to identify novel targets for tumor targeting, perform laboratory testing of new treatment strategies, and develop new biomarkers and clinical trials.[1]
He has authored or co-authored more than 100 publications including articles, abstracts, book chapters, book reviews, and invited manuscripts. Some of his works include:[footnote num=”1″}
BOOKS
- Targeted Therapies for Non-Small Cell Lung Cancer, David E. Gerber (2011), Oxford University Press
- Lung Cancer, Apar K. Ganti, David E. Gerber (2014), Oxford University Press
PUBLICATIONS
- Treatment and Outcomes of Primary Pericardial Mesothelioma: A Contemporary Review of 103 Published Cases, David E Gerber, Jonathan E Dowell, Clinical Lung Cancer
- Randomized phase 3 study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer. Gerber DE, Horn L, Boyer M, Sanborn R, Natale R, Palmero R, Bidoli P, Bondarenko I, Germonpre P, Ghizdavescu D, Kotsakis A, Lena H, Losonczy G, Park K, Su WC, Tang M, Lai J, Kallinteris NL, Shan JS, Reck M, Spigel DR Annals of oncology: official journal of the European Society for Medical Oncology 2018 May
- Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer. Gerber DE, Socinski MA, Neal JW, Wakelee HA, Shirai K, Sequist LV, Rosovsky RP, Lilenbaum RC, Bastos BR, Huang C, Johnson ML, Hesketh PJ, Subramaniam DS, Dietrich MF, Chai F, Wang Y, Kazakin J, Schwartz B, Schiller JH, Brahmer JR, Kelly RJ Lung cancer (Amsterdam, Netherlands) 2018 Mar 117 44-49
- How does autoimmune disease impact treatment and outcomes among patients with lung cancer? A national SEER-Medicare analysis. Khan SA, Pruitt SL, Xuan L, Makris U, Gerber DE Lung cancer (Amsterdam, Netherlands) 2018 Jan 115 97-102
- Institutional Scientific Review of Cancer Clinical Research Protocols: A Unique Requirement That Affects Activation Timelines. Ning N, Yan J, Dietrich MF, Xie XJ, Gerber DE Journal of oncology practice 2017 Oct JOP2017024299
